In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).


Journal

International journal of antimicrobial agents
ISSN: 1872-7913
Titre abrégé: Int J Antimicrob Agents
Pays: Netherlands
ID NLM: 9111860

Informations de publication

Date de publication:
Feb 2019
Historique:
received: 27 06 2018
revised: 12 10 2018
accepted: 20 10 2018
pubmed: 6 11 2018
medline: 17 5 2019
entrez: 6 11 2018
Statut: ppublish

Résumé

Cefiderocol is a siderophore cephalosporin in development for treatment of infections caused by Gram-negative bacilli, including carbapenem-resistant and multidrug-resistant isolates. β-Lactamase carriage and in vitro activity of cefiderocol were determined against 1272 meropenem-non-susceptible isolates of Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii collected as part of the SIDERO-WT-2014 surveillance study. Minimum inhibitory concentration (MIC) values for cefiderocol were ≤4 µg/mL against 97.7% of tested isolates, including 100% of IMP-positive (range, 1-2 µg/mL), OXA-58-positive (MIC

Identifiants

pubmed: 30395986
pii: S0924-8579(18)30299-1
doi: 10.1016/j.ijantimicag.2018.10.007
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
Bacterial Proteins 0
Cephalosporins 0
beta-Lactamases EC 3.5.2.6
carbapenemase EC 3.5.2.6

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

177-184

Informations de copyright

Copyright © 2018 The Authors. Published by Elsevier B.V. All rights reserved.

Auteurs

Krystyna M Kazmierczak (KM)

International Health Management Associates, Inc., Schaumburg, IL, US. Electronic address: kkazmierczak@ihmainc.com.

Masakatsu Tsuji (M)

Drug Discovery & Disease Research Laboratory, Shionogi & Co., Ltd., Osaka, Japan.

Mark G Wise (MG)

International Health Management Associates, Inc., Schaumburg, IL, US.

Meredith Hackel (M)

International Health Management Associates, Inc., Schaumburg, IL, US.

Yoshinori Yamano (Y)

Pharmaceutical Research Division, Shionogi & Co., Ltd., Osaka, Japan.

Roger Echols (R)

Clinical Development and Medical Affairs, ID3C, LLC, Easton CT, US.

Daniel F Sahm (DF)

International Health Management Associates, Inc., Schaumburg, IL, US.

Articles similaires

Vancomycin-associated DRESS demonstrates delay in AST abnormalities.

Ahmed Hussein, Kateri L Schoettinger, Jourdan Hydol-Smith et al.
1.00
Humans Drug Hypersensitivity Syndrome Vancomycin Female Male
Photosynthesis Ribulose-Bisphosphate Carboxylase Carbon Dioxide Molecular Dynamics Simulation Cyanobacteria
Humans Arthroplasty, Replacement, Elbow Prosthesis-Related Infections Debridement Anti-Bacterial Agents
Vancomycin Polyesters Anti-Bacterial Agents Models, Theoretical Drug Liberation

Classifications MeSH